scholarly journals Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy

2019 ◽  
Vol 35 (3) ◽  
Author(s):  
Sabeen Khalid ◽  
Muhammad Javad Yousaf ◽  
Amir Rashid ◽  
Saleem Ahmad Khan
Keyword(s):  
Rheumatoid Arthritis ◽  
Gene Expression ◽  
Drug Therapy ◽  
Military Hospital ◽  
Control Group ◽  
Interleukin 18 ◽  
Down Regulation ◽  
Group I ◽  
Disease Modifying ◽  
Rheumatic Drug

Background & Objectives: The hallmark of rheumatoid arthritis is the inflammation that is mediated by the macrophages and monocytes that cause release of pro-inflammatory cytokines like interleukin-18. It is highly expressed in serum of patients suffering from rheumatoid arthritis and has a positive association with disease activity. The aim of this study was to analyze the gene expression of interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy. Methods: The cross sectional comparative study is conducted at Department of Biochemistry and Molecular Biology and Center for Research in Experimental and Applied Medicine (CREAM-1Lab), Army Medical College, Rawalpindi, in collaboration with Rheumatology Department, Military Hospital, Rawalpindi. Study was conducted on two groups consisting of Group-I of rheumatoid arthritis patients on diseases modifying anti-rheumatic drugs and control Group-II comprising of normal healthy individuals. Non-probability purposive sampling was done from patients and controls. The duration of study was one year i-e from November 2015 to November 2016. Relative quantification of gene expression of interleukin-18 was done by Real time PCR using ∆∆CT method. Results: Expression analysis for interleukin-18 showed down regulation of gene in rheumatoid arthritis patients as compared to controls. Conclusion: Interleukin-18 gene shows down regulation in rheumatoid arthritis patients on disease modifying anti-rheumatic drugs therapy. doi: https://doi.org/10.12669/pjms.35.3.1070 How to cite this:Khalid S, Yousaf MJ, Rashid A, Khan SA. Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy. Pak J Med Sci. 2019;35(3):---------. doi: https://doi.org/10.12669/pjms.35.3.1070 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals 163. A Pictorial Leaflet for Combined Disease-Modifying Anti-Rheumatic Drug Therapy in Early Rheumatoid Arthritis

Rheumatology ◽  
2014 ◽  
Vol 53 (suppl_1) ◽  
pp. i121-i121
Author(s):  
Salini Balendra ◽  
Azeem Ahmed ◽  
Elizabeth Price ◽  
David Collins ◽  
Lyn Williamson
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Therapy ◽  
Early Rheumatoid Arthritis ◽  
Disease Modifying ◽  
Rheumatic Drug

scholarly journals Influence of triple disease modifying anti-rheumatic drug therapy on carotid artery inflammation in drug-naive patients with recent onset of rheumatoid arthritis

Rheumatology ◽  
2016 ◽  
Vol 55 (10) ◽  
pp. 1777-1785 ◽  
Author(s):  
Matti Haavisto ◽  
Antti Saraste ◽  
Laura Pirilä ◽  
Jarna C. Hannukainen ◽  
Kari K. Kalliokoski ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Therapy ◽  
Carotid Artery ◽  
Recent Onset ◽  
Drug Naïve ◽  
Disease Modifying ◽  
Rheumatic Drug

scholarly journals Combination Therapy of Mesenchymal Stromal Cells and Interleukin-4 Attenuates Rheumatoid Arthritis in a Collagen-Induced Murine Model

Cells ◽  
2019 ◽  
Vol 8 (8) ◽  
pp. 823 ◽  
Author(s):  
Shaimaa M. Haikal ◽  
Nourtan F. Abdeltawab ◽  
Laila A. Rashed ◽  
Tarek I. Abd El-Galil ◽  
Heba A. Elmalt ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Gene Expression ◽  
Combination Therapy ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Combined Therapy ◽  
Knee Joints ◽  
Control Group ◽  
Mouse Bone Marrow ◽  
Group I

Rheumatoid arthritis (RA) is a disease of the joints that causes decreased quality of life. Mesenchymal stromal cells (MSCs) have immunosuppressive properties, with possible use in the treatment of RA. Similarly, interleukin (IL)-4 has been shown as a potential RA treatment. However, their combination has not been explored before. Therefore, this study aimed to investigate the effect of a combination therapy of MSCs and IL-4 in the treatment of RA, using a murine collagen-induced arthritis (CIA) model. Arthritis was induced in Balb/c mice by two intradermal injections of type II collagen (CII), at days 0 and 21. CIA mice were randomly assigned to four groups; group I received an intravenous injection of mouse bone marrow-derived MSCs, while group II received an intraperitoneal injection of IL-4. Group III received a combined treatment of MSC and IL-4, while group IV served as a CIA diseased control group receiving phosphate buffer saline (PBS). A fifth group of healthy mice served as the normal healthy control. To assess changes induced by different treatments, levels of RA-associated inflammatory cytokines and biomarkers were measured in the serum, knee joints, and synovial tissue, using ELISA and Real Time-qPCR. Histopathological features of knee joints were analyzed for all groups. Results showed that combined MSC and IL-4 treatment alleviated signs of synovitis in CIA mice, reverting to the values of healthy controls. This was evident by the decrease in the levels of rheumatic factor (RF), C-reactive protein (CRP) and anti-nuclear antibodies (ANA) by 64, 80, and 71%, respectively, compared to the diseased group. Moreover, tumor necrosis factor-alpha (TNF- α) and monocyte chemoattractant protein-1 (MCP-1) levels decreased by 63 and 68%, respectively. Similarly, our gene expression data showed improvement in mice receiving combined therapy compared to other groups receiving single treatment, where cartilage oligomeric matrix protein (Comp), tissue inhibitor metalloproteinase-1 (Timp1), matrix metalloproteinase1 (Mmp-1), and IL-1 receptor (Il-1r) gene expression levels decreased by 75, 70, and 78%, respectively. Collectively, treatment with a combined therapy of MSC and IL-4 might have an efficient therapeutic effect on arthritis. Thus, further studies are needed to assess the potential of different MSC populations in conjugation with IL-4 in the treatment of experimental arthritis.

Sign in / Sign up

Export Citation Format

Share Document